Buy tirzepatide peptide Canada dual agonist research Durham Peptides Tirzepatide represents the second generation of incretin peptide research — the first dual-agonist compound to activate both GLP-1 and GIP receptors simultaneously. For Canadian researchers studying metabolic peptide pharmacology, tirzepatide sits at the intersection of single-agonist semaglutide (older generation) and triple-agonist retatrutide (newer generation), making it a central reference compound for

Buy semaglutide peptide Canada GLP-1 research Durham Peptides Semaglutide is the foundational compound in the incretin peptide research category. As the first GLP-1 receptor agonist to achieve broad clinical research success, it remains the reference compound that newer dual-agonist (tirzepatide) and triple-agonist (retatrutide) compounds are compared against. For Canadian researchers entering the metabolic peptide research space, semaglutide is often the first compound they

Semaglutide vs tirzepatide comparison Canadian research peptides Durham Peptides "Semaglutide vs tirzepatide" is one of the most-searched comparison queries in the Canadian research peptide market, and for good reason. The two compounds sit at the center of the incretin peptide class — the research area that has produced more clinical trial data than any other peptide category in the past decade. For Canadian researchers entering the metabolic peptide space, understanding the

Is tirzepatide a peptide research classification Durham Peptides Canada "Is tirzepatide a peptide?" is one of the most frequently asked questions by researchers and buyers entering the metabolic research space for the first time. The short answer is yes — tirzepatide is a peptide. But because tirzepatide is most commonly encountered under its brand names (Mounjaro and Zepbound) as an approved pharmaceutical, it's often not immediately obvious to people outside the research co